|Daily Range||$24.16 - $24.31|
|52-Week Range||$20.36 - $27.52|
|Dividend (Yield)||$0.00 (2.6%)|
|Average Daily Volume||27,425|
|Current FY EPS||$0.56|
Orexigen Therapeutics is crashing today following more bad news for its diet pill Contrave. Here's what investors need to know right now.
Orexigen Therapeutics shares tumble after the company announces the termination of a critical post-marketing approval study for Contrave.
The pharmaceutical market is headed for $1.3 trillion by 2016. Here's how globalization is radically changing the game for Big Pharma and Big Biotech players.
After reporting first-quarter financials Friday, ImmunoGen Inc.'s shares fell despite bullish analyst reports.
Fourth-quarter earnings were nothing to get excited about, but the Contrave launch trajectory looks good so far.
Instead of Ebola drugmakers, investors may be better served focusing on these healthcare trends.
Motley Fool contributors offer up three potential acquisition targets for Pfizer.
What's the best way to lose weight? One company thinks it's simple: don't get hungry.
Seattle Genetics' shares get hammered following impressive clinical data from its rivals at the American Society of Hematology's annual meeting. Find out whether this dip represents a buying opportunity or a red flag.
Aegerion Pharmaceuticals, MannKind Corp., and VIVUS, Inc. have all attracted short sellers in droves this year. With each company facing serious headwinds, should investors avoid these struggling biotechs?